Keywords: mixed, ph, iib, data, idenix, hcv, combo

Mixed Ph IIb data for Idenix' HCV combo

Article | 23 April 2007

USA-based Idenix Pharmaceuticals presented mixed results from two Phase IIb studies of its novel HCV polymerase inhibitor, valopicitabine (NM283) and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Copegus

Ribavirin

Rebetol

Virazole

Go to drug listing